1. Home
  2. ZLAB vs NAD Comparison

ZLAB vs NAD Comparison

Compare ZLAB & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • NAD
  • Stock Information
  • Founded
  • ZLAB 2013
  • NAD 1999
  • Country
  • ZLAB China
  • NAD United States
  • Employees
  • ZLAB N/A
  • NAD N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • NAD Investment Managers
  • Sector
  • ZLAB Health Care
  • NAD Finance
  • Exchange
  • ZLAB Nasdaq
  • NAD Nasdaq
  • Market Cap
  • ZLAB 3.4B
  • NAD 2.7B
  • IPO Year
  • ZLAB 2017
  • NAD N/A
  • Fundamental
  • Price
  • ZLAB $36.14
  • NAD $11.72
  • Analyst Decision
  • ZLAB Buy
  • NAD
  • Analyst Count
  • ZLAB 3
  • NAD 0
  • Target Price
  • ZLAB $47.37
  • NAD N/A
  • AVG Volume (30 Days)
  • ZLAB 1.3M
  • NAD 595.7K
  • Earning Date
  • ZLAB 05-07-2025
  • NAD 01-01-0001
  • Dividend Yield
  • ZLAB N/A
  • NAD 4.35%
  • EPS Growth
  • ZLAB N/A
  • NAD N/A
  • EPS
  • ZLAB N/A
  • NAD N/A
  • Revenue
  • ZLAB $398,988,000.00
  • NAD N/A
  • Revenue This Year
  • ZLAB $45.57
  • NAD N/A
  • Revenue Next Year
  • ZLAB $47.91
  • NAD N/A
  • P/E Ratio
  • ZLAB N/A
  • NAD N/A
  • Revenue Growth
  • ZLAB 49.59
  • NAD N/A
  • 52 Week Low
  • ZLAB $13.48
  • NAD $9.56
  • 52 Week High
  • ZLAB $37.99
  • NAD $11.64
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 64.46
  • NAD 37.78
  • Support Level
  • ZLAB $34.32
  • NAD $11.82
  • Resistance Level
  • ZLAB $37.99
  • NAD $11.89
  • Average True Range (ATR)
  • ZLAB 1.98
  • NAD 0.07
  • MACD
  • ZLAB 0.02
  • NAD -0.02
  • Stochastic Oscillator
  • ZLAB 72.51
  • NAD 16.67

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

About NAD Nuveen Quality Municipal Income Fund

Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

Share on Social Networks: